This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market

Market Insights on Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment covering sales outlook, demand forecast & up-to-date key trends

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Drug Type, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033

Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market Snapshot (2023 to 2033)

The global Progressive Fibrosing Interstitial Lung Disease market is currently valued at US$ 4742.2 Million in 2023 and is anticipated to expand at a CAGR of 6.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 8654.1 Million by 2033.

The progressive fibrosing interstitial lung disease market is anticipated to increase due to factors such as increased awareness of PF-ILD along with the expected launch of emerging therapies during the forecast period (2023 to 2033).

Report Attribute

Details

Expected Market Value (2023)

US$ 4742.2 Million

Projected Forecast Value (2033)

US$ 8654.1 Million

Global Growth Rate (2023 to 2033)

6.2% CAGR

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.

Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Progressive Fibrosing Interstitial Lung Diseases are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis.

The type-specific segmentation majorly includes Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and ILDs.
Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), are key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive Fibrosing Interstitial Lung Disease is calculated on the basis of the FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.

PF-ILD treatments that act on the fibrotic pathway are required to slow the progression of fibrosis. Other than IPF, there are few treatment options for advanced fibrotic ILD. Pirfenidone use in PPF patients is associated with a statistically significant reduction in disease progression and protection of lung function.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which are Some Prominent Drivers of the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?

Growing Incidences of Infections Cause by Coxsackievirus to Drive the Market Growth

Major factors driving the global progressive fibrosing interstitial lung disease treatment market are an increase in the incidence of lung infections, a surge in awareness among the people, and rigorous government initiatives to reduce the incidence of these infections.

Also, the increasing awareness regarding interstitial lung disease treatment among people, availability of cost-effective drugs in the market, and high prevalence of viral infection-causing lung disorder across the globe is expected to be the key factor driving the growth of progressive fibrosing interstitial lung disease treatment market.

The global progressive fibrosing interstitial lung disease treatment market is anticipated to observe impressive growth during the forecast period, 2023 to 2033. The other factors supporting the market’s growth are, the increasing government investments in research & development activities, the growing footprint of pharmaceutical manufacturers, developed healthcare infrastructure, rising awareness among the masses, and technological advancements.

The adoption of Inorganic Strategies by the Market Players is Expected to Drive Market Growth During the Forecast Period.

The increasing number of partnerships by key players is expected to boost the growth of the global interstitial lung disease market during the forecast period. For instance, in September 2020, Boehringer Ingelheim (Canada) Ltd., a pharmaceutical company, announced that they had entered into a partnership with the University Hospital Foundation (UHF), this partnership will focus on improving patient outcomes in the area of progressive fibrosing interstitial lung disease (PF-ILD).

Which are the Trough Areas faced by the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?

High Expenditures Associated with Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Research and Development

Although the progressive fibrosing interstitial lung disease treatment market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The high cost of drugs for the treatment of lung disease will restrain the growth of this market to some extent.

The high expense of therapies has severely hindered their widespread acceptance, particularly in underdeveloped nations. Such high treatment costs are also a subject of worry in developed nations, as many treatments may not be appropriately reimbursed, raising the patient's out-of-pocket expenditures dramatically.

Some side effects after the consumption of anti-inflammatory drugs will also hinder the growth of the progressive fibrosing interstitial lung disease market. All these factors are expected to derail the progress of the progressive fibrosing interstitial lung disease treatment market.

Many drugs have been withdrawn due to clinical challenges in later stages, implying that current emerging drugs may fail and clinical development failure weakens the emerging pipeline. This will disrupt progressive fibrosing interstitial lung disease treatment market growth.

Other factors such as a lack of sensitive clinical outcomes, suitable biomarkers, and difficulty in recruiting subjects, resulting in project delays or cancellations, are hindering the growth of the progressive fibrosing interstitial lung disease treatment market.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Country-Wise Insights

What Makes USA an Attractive Market for Progressive Fibrosing Interstitial Lung Disease Treatment?

Advancement in Healthcare to Boost the Market Growth in Region

The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 6.0% during the forecast period.

The high prevalence of the disease together with the presence of many leading market players in the region is expected to boost the growth of the North American interstitial lung disease treatment market in the years to come.

The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted for by the US in 2021 (166,393 cases), which are expected to show a rise in the future.

Why Is Europe Emerging as an Opportunistic Progressive Fibrosing Interstitial Lung Disease Treatment Market?

Growing Prevalence of Lung-Related Disorders to Boost the Growth of the Market

Europe is expected to have the second maximum market share of the progressive fibrosing interstitial lung disease treatment market due to the high number of people suffering from COPD and asthma in the region.

Among the European countries, Germany had the highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease with 31,807 cases, followed by the United Kingdom, which had diagnosed cases of 25,446 in 2021. On the other hand, Spain had the lowest diagnosed population (17,834 cases).

In addition, technologically advanced healthcare facilities are contributing to the growth of the market. Moreover, increasing awareness regarding early therapeutics for lung disease is contributing to the growth of the market. Thus, Europe is expected to possess a 56.7% market share in 2023.

Country-wise Forecast CAGRs for Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market

United Kingdom

6.0%

India

5.6%

South Korea

5.7%

China

5.8%

United States of America

6.1%

Category wise Insights

Based on Drug Type, Which Is the Most Prominent Segment in Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?

Corticosteroids Segment to Generate Significantly High Revenue

On the basis of drug type progressive fibrosing interstitial lung disease (PFILD) treatment market is classified into Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, and Others. Among these corticosteroids registers the highest demand in the progressive fibrosing interstitial lung disease treatment market owing to the fewer side effects registered with the usage of this drug as compared to others. Corticosteroids, except nintedanib and pirfenidone, are commonly used as first-line therapies for ILDs other than IPF. Except for acute exacerbations, international guidelines for IPF treatment strongly recommend corticosteroid monotherapy.

The corticosteroids segment held a dominant market share in the year 2023 and is estimated to grow with the fastest CAGR rate of 5.9% over the forecast period 2022to2023.

By Distribution Channel, which segment generates high revenue in the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment market?

Hospital Pharmacy Segment Remains Dominant Among Other Types

The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 65.5%. The growth of the segment is attributed to the increasing prevalence of Progressive Fibrosing Interstitial Lung Disease (PFILD) and hospitalization for treatment.

Hospital pharmacies preserve the stock of products related to Interstitial Lung Disease for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.

The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Start-up Scenario

How do New Entrants Contribute to the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?

With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the progressive fibrosing interstitial lung diseases treatment market.

Some of the start-ups in the progressive fibrosing interstitial lung diseases treatment market include-

  • ILD Insights provides an information app to support the diagnosis and management of lung diseases. The app has features like information and resource materials for healthcare professionals and patient videos featuring opinion leaders, published studies, and clinical practice guidelines.

Competitive Landscape

Some of the key players present in the global progressive fibrosing interstitial lung diseases treatment markets are Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, GNI-EPS Pharmaceuticals, Inc. and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.

  • In February 2022, Boehringer Ingelheim announced that the USA Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF). BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis - irreversible scarring of lung tissue that negatively impacts lung function - and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs)
  • FibroGen is developing pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, a fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases. Other than IPF, FibroGen is also evaluating Pamrevlumab in Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD), and locally advanced unresectable pancreatic cancer (LAPC). Furthermore, as stated by the company, the drug demonstrated the potential for stabilization of disease and reversal of lung fibrosis in some patients.
  • In March 2020 - Roche announced that the USA Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD
  • In March 2021, F. Hoffmann-La Roche Ltd, a biotech company, announced that the USA Food and Drug Administration (FDA) approved Actemra/RoActemra (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the USA FDA for the treatment of the disease.

Report Scope

Report Attribute

Details

Growth Rate

CAGR 6.2% from 2023 to 2033

Expected Market Value (2023)

US$4742.2 Million

Projected Forecast Value (2033)

US$ 8654.1 Million

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in USD Billion & CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis

Segments Covered

  • Drug Type
  • Route of Administration
  • Distribution Channel
  • Regions

Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Key Countries Profiled

  • United States of America
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC Countries
  • South Africa
  • Israel

Key Companies Profiled

  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • FibroGen
  • Hoffmann-La Roche Ltd
  • Pliant Therapeutics, Inc.
  • United Therapeutics
  • Vicore Pharma AB
  • Avalyn Pharmaceuticals
  • Beijing Continent Pharmaceutical
  • GNI-EPS Pharmaceuticals, Inc.

Customization

Available Upon Request

Key Segments Covered in the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market Industry Survey

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Drug Type:

  • Corticosteroids
  • Immune Suppressing
  • Anti-Fibrotic Medication
  • Others

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Route of Administration:

  • Oral
  • Injectable

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market by Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

The global progressive fibrosing interstitial lung diseases treatment market is likely to reach a valuation of US$ 4742.2 million by the end of 2023.

Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics are some of the key players in the global progressive fibrosing interstitial lung diseases treatment market.

Sales of the progressive fibrosing interstitial lung diseases treatment market are likely to expand at 6.2% CAGR through 2033.

The US, Canada, Japan, China, & Germany are expected to drive most of the demand for the progressive fibrosing interstitial lung diseases treatment market.

By the end of 2033, the global market for progressive fibrosing interstitial lung diseases treatment market is predicted to reach a valuation of US$ 8654.1Million.

Table of Content

1. Executive Summary | Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Corticosteroids

        5.3.2. Immune Suppressing

        5.3.3. Anti-Fibrotic Medication

        5.3.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Injectable

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. Middle East and Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Type

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Type

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Type

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Type

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Type

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Type

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Type

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Type

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Type

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Type

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Type

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Type

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Type

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channe

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Type

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Type

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Type

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Type

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Type

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Type

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Type

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Type

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Type

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Type

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Type

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Type

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Type

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Type

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Boehringer Ingelheim

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Bristol-Myers Squibb

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. FibroGen

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Hoffmann-La Roche Ltd

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Pliant Therapeutics, Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. United Therapeutics

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Vicore Pharma AB

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Avalyn Pharmaceuticals

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Beijing Continent Pharmaceutical

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. GNI-EPS Pharmaceuticals, Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Value (US$ Million) Forecast by Region, 2018to 2033

Table 2: Global Value (US$ Million) Forecast by Drug Type, 2018to 2033

Table 3: Global Value (US$ Million) Forecast by Route of Administration, 2018to 2033

Table 4: Global Value (US$ Million) Forecast by Distribution Channel, 2018to 2033

Table 5: North America Value (US$ Million) Forecast by Country, 2018to 2033

Table 6: North America Value (US$ Million) Forecast by Drug Type, 2018to 2033

Table 7: North America Value (US$ Million) Forecast by Route of Administration, 2018to 2033

Table 8: North America Value (US$ Million) Forecast by Distribution Channel, 2018to 2033

Table 9: Latin America Value (US$ Million) Forecast by Country, 2018to 2033

Table 10: Latin America Value (US$ Million) Forecast by Drug Type, 2018to 2033

Table 11: Latin America Value (US$ Million) Forecast by Route of Administration, 2018to 2033

Table 12: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018to 2033

Table 13: Europe Value (US$ Million) Forecast by Country, 2018to 2033

Table 14: Europe Value (US$ Million) Forecast by Drug Type, 2018to 2033

Table 15: Europe Value (US$ Million) Forecast by Route of Administration, 2018to 2033

Table 16: Europe Value (US$ Million) Forecast by Distribution Channel, 2018to 2033

Table 17: South Asia Value (US$ Million) Forecast by Country, 2018to 2033

Table 18: South Asia Value (US$ Million) Forecast by Drug Type, 2018to 2033

Table 19: South Asia Value (US$ Million) Forecast by Route of Administration, 2018to 2033

Table 20: South Asia Value (US$ Million) Forecast by Distribution Channel, 2018to 2033

Table 21: East Asia Value (US$ Million) Forecast by Country, 2018to 2033

Table 22: East Asia Value (US$ Million) Forecast by Drug Type, 2018to 2033

Table 23: East Asia Value (US$ Million) Forecast by Route of Administration, 2018to 2033

Table 24: East Asia Value (US$ Million) Forecast by Distribution Channel, 2018to 2033

Table 25: Oceania Value (US$ Million) Forecast by Country, 2018to 2033

Table 26: Oceania Value (US$ Million) Forecast by Drug Type, 2018to 2033

Table 27: Oceania Value (US$ Million) Forecast by Route of Administration, 2018to 2033

Table 28: Oceania Value (US$ Million) Forecast by Distribution Channel, 2018to 2033

Table 29: MEA Value (US$ Million) Forecast by Country, 2018to 2033

Table 30: MEA Value (US$ Million) Forecast by Drug Type, 2018to 2033

Table 31: MEA Value (US$ Million) Forecast by Route of Administration, 2018to 2033

Table 32: MEA Value (US$ Million) Forecast by Distribution Channel, 2018to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Value (US$ Million) by Drug Type, 2023 to 2033

Figure 2: Global Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 3: Global Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 4: Global Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Value (US$ Million) Analysis by Region, 2018to 2033

Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Value (US$ Million) Analysis by Drug Type, 2018to 2033

Figure 9: Global Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 10: Global Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 11: Global Value (US$ Million) Analysis by Route of Administration, 2018to 2033

Figure 12: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 13: Global Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 14: Global Value (US$ Million) Analysis by Distribution Channel, 2018to 2033

Figure 15: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 16: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 17: Global Attractiveness by Drug Type, 2023 to 2033

Figure 18: Global Attractiveness by Route of Administration, 2023 to 2033

Figure 19: Global Attractiveness by Distribution Channel, 2023 to 2033

Figure 20: Global Attractiveness by Region, 2023 to 2033

Figure 21: North America Value (US$ Million) by Drug Type, 2023 to 2033

Figure 22: North America Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 23: North America Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 24: North America Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Value (US$ Million) Analysis by Country, 2018to 2033

Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Value (US$ Million) Analysis by Drug Type, 2018to 2033

Figure 29: North America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 30: North America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 31: North America Value (US$ Million) Analysis by Route of Administration, 2018to 2033

Figure 32: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 33: North America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 34: North America Value (US$ Million) Analysis by Distribution Channel, 2018to 2033

Figure 35: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 36: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 37: North America Attractiveness by Drug Type, 2023 to 2033

Figure 38: North America Attractiveness by Route of Administration, 2023 to 2033

Figure 39: North America Attractiveness by Distribution Channel, 2023 to 2033

Figure 40: North America Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Value (US$ Million) by Drug Type, 2023 to 2033

Figure 42: Latin America Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 43: Latin America Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018to 2033

Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Value (US$ Million) Analysis by Drug Type, 2018to 2033

Figure 49: Latin America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 50: Latin America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 51: Latin America Value (US$ Million) Analysis by Route of Administration, 2018to 2033

Figure 52: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 53: Latin America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 54: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018to 2033

Figure 55: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 56: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 57: Latin America Attractiveness by Drug Type, 2023 to 2033

Figure 58: Latin America Attractiveness by Route of Administration, 2023 to 2033

Figure 59: Latin America Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Latin America Attractiveness by Country, 2023 to 2033

Figure 61: Europe Value (US$ Million) by Drug Type, 2023 to 2033

Figure 62: Europe Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 63: Europe Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Value (US$ Million) Analysis by Country, 2018to 2033

Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Value (US$ Million) Analysis by Drug Type, 2018to 2033

Figure 69: Europe Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 70: Europe Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 71: Europe Value (US$ Million) Analysis by Route of Administration, 2018to 2033

Figure 72: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 73: Europe Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 74: Europe Value (US$ Million) Analysis by Distribution Channel, 2018to 2033

Figure 75: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 76: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 77: Europe Attractiveness by Drug Type, 2023 to 2033

Figure 78: Europe Attractiveness by Route of Administration, 2023 to 2033

Figure 79: Europe Attractiveness by Distribution Channel, 2023 to 2033

Figure 80: Europe Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Value (US$ Million) by Drug Type, 2023 to 2033

Figure 82: South Asia Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 83: South Asia Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 84: South Asia Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Value (US$ Million) Analysis by Country, 2018to 2033

Figure 86: South Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Value (US$ Million) Analysis by Drug Type, 2018to 2033

Figure 89: South Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 90: South Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 91: South Asia Value (US$ Million) Analysis by Route of Administration, 2018to 2033

Figure 92: South Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 93: South Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 94: South Asia Value (US$ Million) Analysis by Distribution Channel, 2018to 2033

Figure 95: South Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 96: South Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 97: South Asia Attractiveness by Drug Type, 2023 to 2033

Figure 98: South Asia Attractiveness by Route of Administration, 2023 to 2033

Figure 99: South Asia Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: South Asia Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Value (US$ Million) by Drug Type, 2023 to 2033

Figure 102: East Asia Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 103: East Asia Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 104: East Asia Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Value (US$ Million) Analysis by Country, 2018to 2033

Figure 106: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Value (US$ Million) Analysis by Drug Type, 2018to 2033

Figure 109: East Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 110: East Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 111: East Asia Value (US$ Million) Analysis by Route of Administration, 2018to 2033

Figure 112: East Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 113: East Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 114: East Asia Value (US$ Million) Analysis by Distribution Channel, 2018to 2033

Figure 115: East Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 116: East Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 117: East Asia Attractiveness by Drug Type, 2023 to 2033

Figure 118: East Asia Attractiveness by Route of Administration, 2023 to 2033

Figure 119: East Asia Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: East Asia Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Value (US$ Million) by Drug Type, 2023 to 2033

Figure 122: Oceania Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 123: Oceania Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 124: Oceania Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Value (US$ Million) Analysis by Country, 2018to 2033

Figure 126: Oceania Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Value (US$ Million) Analysis by Drug Type, 2018to 2033

Figure 129: Oceania Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 130: Oceania Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 131: Oceania Value (US$ Million) Analysis by Route of Administration, 2018to 2033

Figure 132: Oceania Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 133: Oceania Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 134: Oceania Value (US$ Million) Analysis by Distribution Channel, 2018to 2033

Figure 135: Oceania Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 136: Oceania Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 137: Oceania Attractiveness by Drug Type, 2023 to 2033

Figure 138: Oceania Attractiveness by Route of Administration, 2023 to 2033

Figure 139: Oceania Attractiveness by Distribution Channel, 2023 to 2033

Figure 140: Oceania Attractiveness by Country, 2023 to 2033

Figure 141: MEA Value (US$ Million) by Drug Type, 2023 to 2033

Figure 142: MEA Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 143: MEA Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 144: MEA Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Value (US$ Million) Analysis by Country, 2018to 2033

Figure 146: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Value (US$ Million) Analysis by Drug Type, 2018to 2033

Figure 149: MEA Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 150: MEA Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 151: MEA Value (US$ Million) Analysis by Route of Administration, 2018to 2033

Figure 152: MEA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 153: MEA Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 154: MEA Value (US$ Million) Analysis by Distribution Channel, 2018to 2033

Figure 155: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 156: MEA Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 157: MEA Attractiveness by Drug Type, 2023 to 2033

Figure 158: MEA Attractiveness by Route of Administration, 2023 to 2033

Figure 159: MEA Attractiveness by Distribution Channel, 2023 to 2033

Figure 160: MEA Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Lung Disease Therapeutics Market

Published : July 2017

Healthcare

Airway Disease Treatment Market

Published : March 2017

Healthcare

Lung Cancer Therapeutics Market

Published : February 2022

Healthcare

Lung Cancer Surgery Market

Published : January 2022

Google translate

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market